OTCMKTS:ARGSQ - Argos Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.05
+0.30 (1.20%)

This chart shows the closing price for ARGSQ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Argos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARGSQ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARGSQ

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Argos Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.05.

This chart shows the closing price for ARGSQ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Argos Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/19/2017FBR & Co.Lower Price TargetMkt Perform ➝ Mkt Perform$40.00 ➝ $24.00
3/17/2017Stifel NicolausLower Price TargetHold$24.00
2/23/2017FBR & Co.Reiterated RatingHold
2/22/2017Needham & Company LLCDowngradeBuy ➝ Hold
2/22/2017JMP SecuritiesDowngradeOutperform ➝ Market Perform
2/22/2017FBR & Co.DowngradeOutperform ➝ Market Perform$260.00 ➝ $40.00
2/22/2017Stifel NicolausDowngradeBuy ➝ Hold$28.00
1/17/2017FBR & Co.Reiterated RatingBuy$260.00
12/9/2016Needham & Company LLCReiterated RatingBuy$200.00
(Data available from 11/28/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Argos Therapeutics logo
Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.
Read More

Today's Range

Now: $0.05
Low: $0.05
High: $0.05

50 Day Range

MA: $0.05
Low: $0.05
High: $0.05

52 Week Range

Now: $0.05
Low: $0.02
High: $0.25

Volume

N/A

Average Volume

13,394 shs

Market Capitalization

$571,698.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Argos Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Argos Therapeutics in the last year:
View the latest analyst ratings for ARGSQ.

What is the current price target for Argos Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Argos Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Argos Therapeutics in the next year.
View the latest price targets for ARGSQ.

What is the current consensus analyst rating for Argos Therapeutics?

Argos Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ARGSQ.

How do I contact Argos Therapeutics' investor relations team?

Argos Therapeutics' physical mailing address is 4233 TECHNOLOGY DR, DURHAM NC, 27704. The biopharmaceutical company's listed phone number is 919-287-6300. The official website for Argos Therapeutics is www.argostherapeutics.com.